Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study



Status:Recruiting
Conditions:Neurology, Psychiatric, Psychiatric, ADHD, Autism
Therapuetic Areas:Neurology, Psychiatry / Psychology, Other
Healthy:No
Age Range:6 - 16
Updated:4/21/2016
Start Date:September 2014
End Date:December 2016
Contact:Sophie Shonka, BS
Email:sophia.shonka@seattlechildrens.org
Phone:206-884-7838

Use our guide to learn which trials are right for you!

Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study

The purpose of this study is to determine whether Quillivant XR is effective in the
treatment of ADHD in children with Autism Spectrum Disorder (ASD).

To evaluate the safety and tolerability of low to moderate dose effects of Quillivant XR
(liquid methylphenidate) and to observe changes in ADHD symptoms and functional outcomes in
children with ASD and ADHD. The investigators propose to investigate the low to moderate
dose range of methylphenidate compared with a very low dose with a gradual dose escalation
schedule because children with ASD have been found to be more sensitive to the adverse
effects of methylphenidate (especially in medium to high doses) than children without ASD.

Inclusion Criteria:

- A clinical diagnosis of Autistic disorder or Asperger's disorder by DSM-IV or Autism
Spectrum Disorder by DSM-V.

- A DSM-V diagnosis of ADHD based upon the K-SADS-P.

- Clinical Global Impressions - Severity for ADHD (CGI-S-ADHD) rating > 4.

- Findings on physical exam, labs and ECG are judged to be normal for age with pulse
and blood pressure within 95% of age and gender mean.

- Informed consent by a parent or legal guardian, and assent for children with
developmental age 7 years or older.

- At least one parent fluent in English

Exclusion Criteria:

- History of Seizure disorder (Febrile seizures are non-exclusionary).

- History of Intellectual Disability (IQ< 70)

- Treatment with MAO Inhibitor (or within 14 days following discontinuation of MAO
Inhibitor).

- Other psychotropic medication other than stable dose of Selective Serotonin Reuptake
Inhibitors, which is permitted)

- Known to be hypersensitive to methylphenidate, or other components of Quillivant XR

- Cardiac or other medical contraindications for stimulant trial (e.g., family history
of heart attack at age younger than 40 years, personal history of heart disease,
history of fainting while exercising, structural cardiac abnormalities,
cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other
serious cardiac problems. If any doubt, children will be referred to a cardiologist
for a cardiac clearance.

- Raynaud's disease

- Pregnancy or Breast-feeding.
We found this trial at
1
site
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Principal Investigator: Mark A Stein, Ph.D
Phone: 206-884-1488
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials